Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 8/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 10/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21703261 | 0.86 | MAP4K1 (0.51) | MAP4K1PLK1CNR2 | |
| SCHEMBL21703264 | 0.85 | MAP4K1 (0.50) | MAP4K1PLK1 | |
| SCHEMBL25943953 | 0.84 | MAP4K1 (0.56) | MAP4K1PLK1CNR2 | |
| SCHEMBL21703258 | 0.83 | MAP4K1 (0.52) | MAP4K1 | |
| SCHEMBL21702950 | 0.83 | MAP4K1 (0.51) | MAP4K1 | |
| SCHEMBL21702951 | 0.83 | MAP4K1 (0.50) | MAP4K1HDAC1 | |
| SCHEMBL21685761 | 0.81 | MAP4K1 (0.49) | MAP4K1 | |
| SCHEMBL21684651 | 0.73 | MAP4K1 (0.47) | MAP4K1 | |
| SCHEMBL21703186 | 0.70 | TBXA2R (0.50) | MAP4K1 | |
| SCHEMBL21703260 | 0.70 | MAP4K1 (0.49) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020033784-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | MAP4K1 2520/4885PLK1 3094/4885CNR2 3766/4885 |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | MAP4K1 2520/4885PLK1 3094/4885CNR2 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.